Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Ekso Is Set to Conquer the Most Valuable Unstoppable Trend of All (OTCBB: EKSO)

What I am about to tell you could reshape labor markets and, in the process, create an entirely new group of millionaires savvy enough to cash in.

Here's the scoop.

Last year I told you about one of the most inspirational companies I've ever visited, Ekso Bionics Inc. (OTCBB: EKSO).

At the time, the company was almost completely off the radar and totally unknown to both investors and analysts alike.

I promised you that wouldn't be the case for long because the company had something other small startups didn't: real products, real customers, and applications that potentially extended sales far beyond the medical and military markets it had initially targeted.

I also told you that the company would attract a lot more capital down the road once others saw the potential… as long as management continued to produce results.

OTCBB: EKSOI've italicized that word because good ideas are a dime a dozen. Over the course of 35 years of analyzing companies, I've seen more than a few seemingly great companies blow up because they couldn't execute. For every Apple or Google, there are thousands of startups that didn't make it.

That's why I'm so focused on seeing what's next. It's also why I won't recommend any company to you without the potential to double in five years or less… at a minimum.

By all accounts, Ekso Bionics is on track and producing results that make it more valuable by the day.

Here are a few key excerpts from last week's earnings release:

  • Year-over-year revenue growth is 54.55%.
  • Ekso Labs just received its second government contract this year and is now working on its third U.S. government exoskeleton project.
  • The company has had an additional three patents granted.
  • The company's first distributor is now fully certified and trained up.
  • Ekso's now sold and/or rented 125 medical devices to more than 90 customers, including 12 with multiple units on location. Of note, medical revenue is up 87%.
  • Ekso is now field testing new proto types and has made several new key hires, including Tom Mastaler, the former head of global operations for Milwaukee Electric Tool Corp.
  • And last but not least, the company turned in a net loss of only $4.1 million or $0.04 per share, versus a net loss of $81.8 million the same period in 2014.

It's no wonder analysts are finally coming around. Though "falling all over themselves" is more like it…

Join the conversation. Click here to jump to comments…

About the Author

Keith Fitz-Gerald has been the Chief Investment Strategist for the Money Morning team since 2007. He's a seasoned market analyst with decades of experience, and a highly accurate track record. Keith regularly travels the world in search of investment opportunities others don't yet see or understand. In addition to heading The Money Map Report, Keith runs High Velocity Profits, which aims to get in, target gains, and get out clean. In his weekly Total Wealth, Keith has broken down his 30-plus years of success into three parts: Trends, Risk Assessment, and Tactics – meaning the exact techniques for making money. Sign up is free at totalwealthresearch.com.

Read full bio

  1. James | May 21, 2015

    Hey Keith,

    Just moments before I saw you as a commentator on Bloomberg television the other day, EKSO appeared on the full screen. Are you the driver pitching EKSO on Bloomberg television? And Fox News, etc.?

    • Keith Fitz-Gerald | May 22, 2015

      Hello James,

      I can see how that would appear to be the case but, no. I am not a pitchman for Ekso or any other stock for that matter. I have never discussed EKSO in any media appearance. Like all our recommendations, EKSO rose to the top by virtue of concerted analysis and ongoing independent research related to the company, its products and its potential. Further, our entire organization – myself included – has strict policies against personal ownership, endorsement and compensation to prevent conflicts of interest.

      Best regards and thank you for being part of the Money Morning Family,

      Keith :-)

  2. John Fuller | June 2, 2015

    Keith,

    A severe drop today on a report that is polar opposite of yours. I also notice that this stock is not part of the Total Wealth or MM recommendations list after the heavy recommendation.

    Comments on how this will play out are greatly appreciated,

  3. BALDWIN25074 | June 2, 2015

    Video shows Rewalk's exoskeleton as far more effective and half the cost. Insider selling, hiring fraudster to promote stock and turnover in company management does not bode well for success. Is EKSO truly positioned for success. Please convince me. Appreciate that you will comment Wednesday.

    • Tim Retter | June 14, 2015

      If speed is your only metric, with out surrounding evidence, you might be right. In the video your talking about, the guy in the Rewalk Suit might have had 100 times the experience. The Ekso unit might have just been on a slow training mode as well. The expensive cost of Ekso comes from the much greater technology it uses. If you actually take a look at Ekso's patents vs Rewalk patents; it makes the Rewalk Patents look like they were written by a little kid. Ekso physics is FAR superior, which I can tell you as an undergrad physics student. The Rewalk system is essentially 2 joints and a balancing system. Ekso mimics a real body much better. The US government would have contracted Rewalk if they thought it was a better system.

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK